GenScript, GenScript Pro, and Legend Biotech Will Attend the 42nd JPM Conference
GenScript ProBio Partners With NuclixBio to Pave the Way for South Korea’s First Large-scale Production Process for “Circular RNA Therapeutics”
PISCATAWAY, N.J. & NEW YORK--(BUSINESS WIRE)--GenScript ProBio, a global contract development and manufacturing organization, and Comprehensive Cell Solutions (CCS), a leader in cell therapy development and manufacturing, have partnered to spearhead the development of cell and gene therapies, offering a unique and seamlessly integrated solution that spans cell collections and apheresis through cryopreservation of final therapeutics.
Recently, Eutilex, a partner of GenScript ProBio, announced MFDS clearance of its hepatocellular carcinoma clinical trial application for innovative CAR-T program (EU307). GenScript ProBio extends congratulations on this. 2 years ago, GenScript ProBio and Eutilex announced that the parties entered into strategic collaboration on plasmid and virus process development and manufacturing for multiple CAR-T programs.
GenScript Biotech Corp., a provider of life-science research tools and services, has expanded its Singapore facility to provide a premium gene synthesis service.
GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), and RVAC Medicines Pte. Ltd., a biotechnology company focusing on the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines, entered a strategic partnership for the manufacturing of GMP-grade plasmid DNA (pDNA) for its mRNA COVID-19 vaccine candidate, RVM-V001, along with collaboration for future therapeutic pipelines.
GenScript ProBio, a biologics contract development and manufacturing organization (CDMO) to the biopharmaceutical market, and Bio Immunitas, a UK pharmaceutical company with a novel, safe and efficacious human Recombinant Protein Platform (hRPP), announced a partnership for developing potential novel therapies for clinical use.
China’s GenScript has brought in new investors to back its biologics-focused subsidiary — to the tune of $224 million.
Applied Cells Inc. and GenScript USA Incorporated have entered a strategic collaboration to deliver combined cell isolation solutions for cell therapy drug development worldwide.